Coastal Infusion Administers Elfabrio®
| J-Code | J2508 |
|---|---|
| Manufacturer | Chiesi |
| First Approved | 05/10/2023 |
Coastal Infusion can administer your Elfabrio prescription at any of our south Florida locations.
Elfabrio (pegunigalsidase alfa-iwxj) is as an enzyme replacement therapy which is used for the treatment of Fabry disease. Fabry disease is a rare genetic disorder that is caused by a deficiency of the alpha-galactosidase, an enzyme that leads to the accumulation of a fatty substance called globotriaosylceramide (Gb3) in various tissues and organs.
Elfabrio is an enzyme replacement therapy designed to replace the human enzyme alpha-galactosidase A, which is lacking in patients with Fabry disease.
The active substance in Elfabrio, pegunigalsidase alfa, is a copy of the human enzyme, produced by a method known as recombinant DNA technology. The replacement enzyme helps to break down Gb-3 and stops it building up in the patient’s cells.
What It Treats
Eleprase is used to treat Fabry Disease.
Prescribed By
Elfabrio is most often prescribed by Geneticists, Nephrologists, and Cardiologists.
How it’s Administered
Elfabrio is administered by intravenous infusion. Elfabrio infusions take three to four hours for the first 4 to 6 infusions, then about 90 minutes for subsequent treatments.
Frequency
Elfabrio is generally administered every two weeks.
Related Drugs
Additional Resources
The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies